PHOSP-I

This study is investigating whether Tocilizumab, a medication currently used to treat people in hospital with Covid-19, can help reduce symptoms of long Covid.

Tocilizumab is an anti-inflammatory medication that has been used for many years. This study will test whether treating people with symptoms of long Covid such as fatigue, fever, joint or muscle pain and ongoing inflammation, will help them feel better.

This study is part of PHOSP-COVID (post-hospitalisation Covid-19), a consortium of leading researchers and clinicians across the UK working together to understand and improve long-term health outcomes for people who have had Covid-19. It is led by a team of researchers at the University of Leicester and University Hospitals of Leicester NHS Trust under the umbrella of NIHR Leicester Biomedical Research Centre.

This study is taking place at several sites across England. Research for the Future is currently supporting recruitment at the following locations: Salford Royal Hospital

• Age 18+
• Confirmed diagnosis of long Covid
• Registered with a GP in Salford

• Salford Royal Hospital (M6 8HD)

Taking part will involve

• Having weekly/fortnightly injections of the study drug over 12-weeks*
• Attending up to 16 clinic appointments over the 26- week study period. These will include a range of tests (eg body measurements, blood and urine samples, and lung function and breathing tests) as well as completing questionnaires about your health and how long Covid affects you.

*Participants will be randomly selected to receive either the study drug or a placebo

Participants will receive a small inconvenience payment and reasonable travel expenses will be reimbursed.

Contact Us